News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global Liquid Biopsy Market Outlook 2023”, every year more than 200,000 Americans are diagnosed with lung cancer, and of these, around 80-85% have non-small cell lung cancer (NSCLC). About 10-30% of these NSCLC patients carry EGFR mutations, which serve as an oncogenic driver for this disease. As a result, EGFR mutation status helps physicians determine which treatment options are likely to benefit patients with metastatic NSCLC. For this reason, EGFR testing is required to provide personalized treatment options and better outcomes for NSCLC patients. In this regard, a new method of mutation identification has been introduced, which is known as liquid biopsy. By requiring only a simple blood draw, liquid Biopsy provides a non-invasive alternative for EGFR mutation testing in NSCLC patients when tissue biopsies cannot be obtained or the available specimen is not enough.
 
Numerous Liquid biopsy players are actively working in this field using their proprietary technologies. Indeed, many currently approved therapies are aimed at EGFR mutations and ALK rearrangements. For instance, in 2016, the Food and Drug Administration approved the first liquid biopsy test to screen the blood plasma of patients with metastatic non-small cell lung cancer who may have particular mutations in the EGFR gene, including T790M mutations. This test may help physicians’ select eligible patients with NSCLC for therapy with an EGFR tyrosine kinase inhibitor (TKI).
 
Research Analysis and Highlights
 
The report provides an in-depth research and rational analysis of the current status and future prospect of the Global Liquid Biopsy Market Outlook 2023. The study presents a transparent picture about the current and future market outlook, in terms of the sample type, technology and geography. The report also provides a comprehensive insight about the market dynamics including the drivers, challenges, opportunities, and upcoming trends that would influence the market.
 
The report also covers detailed information about key players in the global liquid biopsy market, to enable the clients to understand the market structure and its growth during the forecasted period. In brief, the report, “Global Liquid Biopsy Market Outlook 2023”, covers all the necessary aspects of the global liquid biopsy market, providing an in-depth research and prudent analysis of the key segments.

Some of the key highlights of the report include the following:
 

• Growth drivers such as increasing prevalence of Cancer; increasing demand for minimally-invasive biopsy techniques; low cost and growing investment for liquid biopsy market
• Detailed analysis of commercialized liquid biopsy products
• Holistic view of the liquid biopsy market, segmentation in terms of the sample type, the technology, pipeline analysis and the regional prevalence
• Leading players and their product portfolio in the liquid biopsy market

 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM924.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm